A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
160actual
Sites
50
Countries
Belgium, Canada, Czechia +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-12-20 | actual | When the study began enrolling |
| Primary completion | 2025-10-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-12 | actual | The whole study's end, after follow-up |
| First posted | 2019-11-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Psoriasis
Intervention
- Drug: Apremilast — also filed as CC-10004, Otezla
Primary outcomes
what the primary-completion date above is the date OFAdverse Events (AEs)
measured Up to approximately 4 years
Columbia-Suicide Severity Rating Scale (C-SSRS)
measured Collected at each study visit throughout the life of the study - up to 4 years
Weight of patients treated with Apremilast
measured Collected at each study visit throughout the life of the study - up to 4 years
Mean body mass index of the patient treated with Apremilast
measured Collected at each study visit throughout the life of the study - up to 4 years
Height patients treated with Apremilast
measured Collected at each study visit throughout the life of the study - up to 4 years
Assessment of sexual maturity
measured Collected every 52 weeks throughout the life of the study - up to 4 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed